Back to search

Article

Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control study

2026-07-16

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> We sought to determine the changing prevalence, incidence, and temporal trends in real-world, recorded diagnoses of metabolic dysfunction-associated steatotic liver disease (MASLD) and assess availability of fibrosis risk stratification following awareness campaigns and guideline updates over the last decade. <h4>Methods</h4> This population-based cohort study identified MAS...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c7156de8-f4fc-52d1-90c4-950b42783e73
DOI
10.64898/2026.07.15.26358136
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control studyDOI 10.64898/2026.07.15.26358136
Unveiling the Burden of MASLD and Liver Fibrosis in India: Novel Insights from the Phenome India Study into fibrosis without MASLDSemantic proximity
Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.Semantic proximity
Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.Semantic proximity
Association of Antihypertensive Medication and Steatotic Liver Disease with Liver Fibrosis and Mortality among US AdultsSemantic proximity
Steatosis Non-Invasive Tests Accurately Predict Metabolic Dysfunction-Associated Steatotic Liver Disease, While Fibrosis Non-Invasive Tests Fall Short: Validation in U.S. Adult PopulationSemantic proximity
Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Semantic proximity
Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.Semantic proximity
Cohort Profile: TRacing Etiology of Non-communicable Diseases (TREND): Rationale, Progress and PerspectiveSemantic proximity
Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD.Semantic proximity
Age-stratified Analysis of Associations Between Participant’s Characteristics and NAFLDSemantic proximity
Reference Interval of Enhanced Liver Fibrosis (Elf) Score in Healthy Multi-ethnic Malaysian PopulationSemantic proximity
Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (<i>PNPLA3</i>and<i>TM6SF2</i>) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank studySemantic proximity
Select a neighboring publication to make it the new centre.